UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, vol.15, no.3, pp.115-119, 2005 (SCI-Expanded)
The aim of this study was to investigate the effect of pretreatment LDH levels on the prognosis of patients with non-small-cell lung cancer. Ninety-six patients who were diagnosed with non-small-cell lung cancer in the departments of medical oncology and chest disease of Karadeniz Technical University and the department of medical oncology of Ankara University and had LDH measurements were included in the study. Normal LDH level group had significantly better prognosis (12.9 months) compared to high LDH level group (6.5 months) (p=0.0011). In the subgroup analysis of LDH groups, the groups were statistically uniform in age, sex, performance status, stage and preferred treatment modality (surgery, radiotherapy, chemotherapy) parameters. The poor prognosis, seen in high LDH level group may be due to their resistance to chemotherapy and high recurrence and low remission rates. More comprehensive studies are needed in this area.